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Abstract:  
With the fast growth of cancer research, new analytical methods are needed to measure 
anticancer drugs. This is usually accomplished by using sophisticated analytical instruments. 
Biosensors are attractive candidates for measuring anticancer drugs, but currently few biosensors 
can achieve this goal. In particular, it is challenging to have a general method to monitor various 
types of anticancer drugs with different structures. In this work, a biosensor was developed to 
detect anticancer drugs by modifying carbon paste electrodes with glutathione-s-transferase 
(GST) enzymes. GST is widely studied in the metabolism of xenobiotics and is a major 
contributing factor in resistance to anticancer drugs. The measurement of anticancer drugs is 
based on competition between 1-chloro-2,4-dinitrobenzene (CDNB) and the drugs for the GST 
enzyme in the electrochemical potential at 0.1 V vs Ag/AgCl by square wave voltammetry 
(SWV) or using a colorimetric method. The sensor shows a detection limit of 8.8 M cisplatin 
and exhibits relatively long life time in daily measurements.   
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1. INTRODUCTION 
In the past few decades, a number of important anticancer drugs have been approved for clinical 
use, including cisplatin, carboplatin, oxaliplatin, gemcitabine, pirarubicin and doxorubicin. The 
efficacy of these drugs however depends on the intrinsic and acquired resistance of patients 
during treatment, which is a major problem in cancer therapy (Koberle et al. 2010). Drug 
resistance is partly attributed to reactions catalyzed by glutathione-s-transferases (GSTs). In 
humans, GSTs are expressed in large amounts, counting for ~4% of the total soluble proteins in 
the liver, which is the main detoxification organ (Smith et al. 2006). GST is a detoxification 
enzyme, catalyzing glutathione (GSH) conjugation reactions. GSH is a tri-peptide that maintains 
a stable redox environment of cells and therefore protects cells from xenobiotic substances.  
A GST has two substrate binding domains: one domain is highly selective for GSH and 
the other binds anticancer drugs by providing a hydrophobic environment (Stewart 2007). Since 
most anti-cancer drugs are quite hydrophobic, they act as good substrates for GST. At the same 
time, GST activates the thiol group on GSH for nucleophilic attacking drug substrates, yielding 
GSH adducts (see Figure 1A for reaction with cisplatin). This type of reaction decreases the 
concentration of free anti-cancer drugs inside cells and thus decreases toxicity. Therefore, an 
increased concentration of GSH or GST might be related to drug resistance in cancer therapy 
(Nussbaumer et al. 2011).  
Monitoring the concentration of anticancer drugs is required to optimize therapy and 
avoid over or under dosage. It is also critical to have convenient analytical methods to monitor 
the effect of GST. In the past few decades, a variety of methods for detecting anticancer drugs 
have been reported. These mainly include high-performance liquid chromatography coupled with 
various kinds of detectors (Desai et al. 2004; Jacquet et al. 1992; Khuhawar and Arain 2005; 
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Martincic et al. 2012; Yaroshenko et al. 2013), such as fluorescence (Shire and Loppnow 2012), 
UV-vis absorption (Menon et al. 2012) and electrochemistry (Dospivova et al. 2012; Teradal et 
al. 2012; Ting et al. 2009). These methods are very accurate, but are quite expensive to carry out. 
Biosensors may be another option for detection and provide complementary information. In 
recent years, many new biomolecules including enzymes, antibodies and aptamers have been 
developed to serve as probes (Chen et al. 2012; Li et al. 2010; Liu et al. 2009; Wang et al. 2013; 
Willner and Zayats 2007). Given the structural diversity of anticancer drugs (Figure 1B), it is 
quite challenging to come up with a different probe for each drug molecule. Since GST is a 
general detoxification enzyme, we hypothesize that it might detect all these drugs. The activity of 
GST can be measured using chromogenic substrates such as 1-chloro-2,4-dinitrobenzene 
(CDNB), which turns a yellow color upon reaction with GSH (Figure 2A), where GST serves as 
a catalyst (Zhao et al. 1993). Since anticancer drugs compete for GSH and GST, they may act as 
inhibitors for the CDNB reaction. This could provide an optical means for monitoring the drugs. 
While optical assays might work in clean buffers, clinical samples are likely to contain blood 
serum or cell extract, which strongly scatter light and interfere with optical detection (Petrlova et 
al. 2006). To this end, electrochemistry-based methods are more useful since they can work well 
in complex sample matrix. To the best of our knowledge, electrochemistry detection of 
anticancer drugs has only been reported using surfactants (Teradal et al. 2012), DNA (Dospivova 
et al. 2012), multi-walled carbon nanotubes (Wang et al. 2012) and nanoparticles (Ting et al. 
2009; Zhou et al. 2007). In those methods, drug recognition was based on simple adsorption or 
DNA intercalation, leading to compromised selectivity. On the other hand, no previous studies 
explored GST-based biosensors for anticancer drug detection. We reason that using GST as a 
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probe might be more relevant to the native cellular environment. In this work, we modify carbon 
paste electrodes with GST to measure cisplatin and others drugs.  
 
 
Figure 1. (A) A proposed mechanism of inactivation of cisplatin by GSH catalyzed by GST. (B) 
Structures representative drugs used in chemotherapy. (C) Schematics of our sensing strategy. A 
carbon paste electrode is modified with GST. The conversion of GSSG to GSH gives the 
electrochemical signal. This signal is enhanced by reacting GSH with CDNB, but is weakened 
by the further addition of anti-cancer drugs such as cisplatin. The electrochemical signal is the 
result of inhibition of GST by anticancer drugs. The amounts of anticancer drugs are monitored 
by the decreased of current caused by an increased the drug concentration in the electrochemical 
cell; the drugs produced a competition with the substrate (CDNB). 
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2. EXPERIMENTAL SECTION 
2.1. Chemicals and preparation of solutions. 
Glutathione-s-transferase from equine liver (GST), glutahione (reduced), 1-chloro-2,4-
dinitrobenzene, cis-diamminedichloro platinum (II), pirarubicin, gemcitabine hydrochloride, 
carboplatin, oxaliplatin, pirarubicin, doxorubicin hydrochloride, potassium chloride, 
glutaraldehyde and 1-chloro-2,4-dinitrobenzene (CDNB) were  purchased from Sigma-Aldrich 
(St. Loius, MO, USA). Phosphate buffer (pH 6.5) was prepared by mixing NaH2PO4 and 
Na2HPO4 . Glutaraldehyde (0.5%) was dissolved in phosphate buffer (pH 6.5, 50 mM). The GSH 
solutions were prepared in the phosphate buffer. GST solution was also dissolved in the 
phosphate buffer and stored at -20 C. All the drugs were dissolved in Milli-Q water. 
2.2. Electrochemical measurements 
Electrochemical measurements were performed with the Palmsense® at room 
temperature, using a standard electrochemical cell with three-electrode. The working electrode 
was carbon paste electrode (3 mm diameter) purchased from Basi. A Pt wire was used as counter 
electrode and Ag/AgCl/3M KCl was the reference electrode.  
2.3. Colorimetric detection 
The GST catalyzed reaction between DCNB and GSH produces GS-DCNB, which is a 
dintrophenyl thioether that was detected by a spectrophotometer (Agilent 8453A) at 340 nm or 
using a spectraMax M3 multi-mode microplate reader. The temperature was set at 37 C and 
reaction kinetics was monitored for 30 min. 
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2.4. Construction of the biosensor 
 The proposed biosensor was constructed using GST as the probe. The carbon paste was 
prepared by homogenizing 100 mg graphite powder, a final of 2.5 mg mL-1 of GST and 0.5% 
glutaraldehyde dissolved in phosphate buffer (pH 6.5, 50 mM) with a total volume of 400 µL. 
The mixture was dried in a refrigerator at 4 C for 24 h, after which 50 µL mineral oil was added 
to obtain a carbon paste. The carbon paste was then inserted into the cavity (3 mm i.d, 5 mm 
depth) of commercial working electrodes. The biosensor response was evaluated using various 
concentrations of GST ranging from 0 to 2.5 mg mL-1. The biosensor was evaluated using square 
wave voltammetry (SWV) and cyclic voltammetry (CV). The solutions of CDNB, GSH and 
cisplatin was prepared fresh daily. CDNB was dissolved with 1.5% acetone and diluted in PBS 
(pH 6.5, 50 mM). 
   
3. RESULT AND DISCUSSION 
3.1. Colorimetric detection.  
1-chloro-2, 4-dinitrobenzene (CDNB) reacts with GSH producing a dinitrophenyl thioether, 
which is a yellow colored product (Hansson et al. 1999). This reaction is catalyzed by GST 
(Figure 2A). CDNB has an absorption peak at 340 nm and this peak increases as the reaction 
proceeds. Note that the tailing of this peak into the visible region is responsible for the yellow 
color. The color of CDNB remained quite stable in the absence of GSH and GST (black line, 
Figure 2B). A slow color change was observed in the presence of GSH (red line) and the rate 
increased with increasing concentration of GST. Therefore, CDNB can be used as a substrate for 
GST activity assay (Zablotowicz et al. 1995), but it has not yet been applied for monitoring 
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anticancer drugs. We determined the optimal concentration GST to be 2.5 mg mL-1 since it 
produces a fast color change in less than 20 min. We also optimized the reaction as a function of 
buffer pH. Optimized activity was achieved at pH 7, where the optical signal was the highest 
(Figure 2C). 
 
 
Figure 2: (A) GST catalyzed reaction between GSH and CDNB, generating a yellow adduct. (B) 
Absorbance at 340 nm of CDNB mixed with GSH in the presence of various concentrations of 
GST. The reaction was carried out in 50 mM PBS (pH 6.5) at 37 C. The control sample does 
not contain any GST. (C) Optimization of pH for the GST catalyzed reaction. (D) Inhibition of 
this reaction by cisplatin. 
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Cisplatin is a classic anticancer drug and we used it as a model for our study. We found 
that the 340 nm peak intensity decreased with increasing cisplatin concentration (Figure 2D). 
Therefore, cisplatin inhibits the color generation of CDNB. This was attributed to the 
competition between cisplatin and CDNB for GST/GSH. As some GST reacts with cisplatin and 
the fraction left to react with CDNB is decreased. Therefore, this inhibition reaction might be 
useful for detecting cisplatin, which serves as an inhibitor. In real blood serum samples, 
however, it is difficult to achieve optical detection due to interference from light scattering. For 
this reason, electrochemistry might be a better route for sensor development.  
 
Figure 3: (A) CV of carbon paste electrode unmodified and modified with GST at potential 
between -0.4 and 0.8 V. Supporting electrolyte was 50 mM PBS (pH 6.5); scan rate = 0.1 V/s. 
(B) CV of carbon paste electrode modified with GST showing response of the substrates and the 
inhibition effect of cisplatin. With GSH, the enzyme modified electrode shows a small increase 
in current, which is attributed to the redox reaction of GSH to GSSG (red line). When CDNB is 
added without GSH, a stronger signal is observed (green line). This is attributed to the reaction 
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of CDNB with the electrode. When GSH and CDNB are added together, a large increase in 
current is observed (gray line) since both substrates of GST are present. As GSH being 
consumed, the conversion from GSSG to GSH becomes more efficient. Finally, when the 
inhibitor (cisplatin) is introduced to compete with the substrate, a decrease of the current is 
observed (blue line). (C) SWV spectra under optimized conditions: 50 mM phosphate buffer (pH 
6.5) with increasing cisplatin concentrations. [GSH] = [CDNB]= 1 mM, [cisplatin] in mM: a = 0; 
b= 0.05; c= 0.065 d= 0.079; e= 0.09; f= 0.10; g=0.11; h=0.12; i= 0.14. (D) Quantification of the 
peak current drop as a function of cisplatin concentration, n = 4; RSD = 4.2%. (E) Stability of 
GST enzyme electrode in the electrochemistry measurements over 15 days.  
 
3.2. Enzyme immobilization for electrochemical detection 
Unlike homogenous optical detection, GST needs to be immobilized to achieve 
electrochemical detection. To characterize GST immobilization, CV experiments were 
performed in the absence and presence of GST (Figure 3A). The amount of GST used in the 
carbon past electrode was based on the colorimetric analysis established in Figure 2B. The 
electrode without modification did not show any obvious redox peaks. The electrode modified 
with GST showed a greater capacitive current with an oxidation peak at 0.15 V and a reduction 
peak at 0.05 V vs Ag/AgCl (in 3 M KCl), indicating successful modification of the electrode 
with GST. The capacitive current increase was attributed to the crosslinking of the immobilized 
GST by glutaraldehyde on the electrode surface, which could cause charge accumulation. 
Impedance and IR spectroscopy measurement also confirmed successful enzyme immobilization 
(see Supplementary Material, Figure S1 and S2). 
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After immobilization, we next analyzed the sensor response at several different stages 
(Figure 3B). Now compared to other signals, the GST modified electrode has a very low current 
(black curve). Note the scale difference of the y-axis in Figure 3A and 3B. Next, 1 mM GSH was 
added, where the CV curve shows an anodic peak current (red trace, Figure 3B). This current is 
attributed to the conversion between GSSG (the oxidized form) and GSH (the reduced form). 
The current increased significantly with the addition of 1 mM CDNB (green curve) since CDNB 
can also react with the electrode surface. We observed the maximal peak current with GSH and 
CDNB both present (gray curve). Under this condition, both substrate binding sites of GST are 
occupied: one with GSH and the other with CDNB. The consumption of GSH may accelerate the 
GSSG react. With the further addition of cisplatin, an inhibition effect occurred with decreased 
electrochemistry signal due to competition (blue curve). This experiment suggests that the 
enzyme modified electrode could detect cisplatin in a way similar to the optical sensor described 
above. The scheme of this sensing strategy is presented in Figure 1C. 
3.3. Quantification of cisplatin using square wave voltammetry (SWV) 
Under optimized conditions, we measured the sensitivity of the sensor. The quantification 
was based on SWV, evaluating inhibition in the presence of cisplatin. We chose to use SWV 
since it can reach a faster scanning rate and thus lower consumption of electroactive compounds. 
It can also discriminate capacitance current more efficiently, allowing broader dynamic range 
(Dogan-Topal et al. 2010). As shown in Figure 3C, the current progressively decreased with 
increasing cisplatin concentration. This electrode shows a linear response between 0.05 and 0.14 
mM cisplatin. The limit of detection was determined to be 8.8 µM cisplatin based on signal 3σ/s, 
where σ is the standard deviation of the intercept and s is the slope of the calibration curve 
(Figure 3D). This sensitivity is comparable with other detection methods based on HPLC and 
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atomic absorption spectrometry (Bosch et al. 2008), but is not as sensitive as ICP-MS and RP 
HPLC-MS (Martincic et al. 2012; Yaroshenko et al. 2013). On the other hand, the GST-based 
biosensor is lower in cost, faster in response time (5 min) and simpler compared to those more 
sensitive instrument-based methods. 
3.4. Stability of the GST enzyme electrode    
For analytical applications, it is important to have a stable sensor that produces reliable 
signals over a long period of time. In Figure 3E, the peak current values were obtained in SWV 
over 15 days. GST enzyme immobilized on the surface of the carbon paste electrode showed 
decreased activity overtime. In this study the electrochemical response of cisplatin on the first 
day of analysis showed a peak current of 102 μA, which was the maximum value. In the 
following days, the electrode was polished before each measurement but without immobilization 
of new enzymes. In other words, the enzymes previously entrapped in the electrode were used. 
The current value decreased progressively reaching a current of 55 μA on day 15 of analysis. 
Compared to day 1, a 47% loss of the current signal was observed. The loss of signal could be 
related to the denaturation or leaching of the enzyme and also possible adsorption of the reaction 
products, blocking substrate access. Although the absolute current decreased, since 
quantification can be realized by measuring the relative current change, a simple calibration 
before analysis could solve this signal decay problem. Therefore, this biosensor offers a rapid 
and effective renewal of the surface layer allowing the use of a single modified carbon-paste 
electrode in multiple analytical measurements over a long time.  
3.5. Analysis of other anticancer drugs and metabolites. 
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Most of our above studies employed cisplatin as a model drug, but there are a few other 
commonly used drugs . The biosensor was also tested with these drugs using SWV and UV-vis 
spectroscopy (Table 1). All the drugs inhibited the sensor signal and inhibition was higher when 
analyzed by UV-vis spectrophotometry. This difference could be related the property of each 
analytical method. The spectrophotometric assays were performed with the GST enzyme free in 
solution, where the activity and inhibition were more pronounced. The electrochemical method 
has relatively smaller inhibition, which might be related to the high background signal in 
electrochemical measurements. Despite the smaller signal change, GST immobilized on the 
electrode surface has the advantage of being reused by polishing electrode surface. Thus GST is 
available for a longer time than that in solution. Among all drugs analyzed, pirarubicin and 
oxoplatin showed stronger interaction with GST, as they gave greater inhibition. It was difficult 
to detect doxorubicin by UV-vis spectroscopy because it has an intense red color that masks the 
weaker absorption by CDNB. Taken together, we conclude that this GST-based biosensor is not 
specific for a particular drug, but is general for many anticancer drugs.  
 
Table 1: The sensor response to anticancer drugs using UV-vis spectroscopy and 
electrochemistry detection. The concentration of the drugs was 0.1 mM.  
Drugs 
Percentage of inhibition 
Electrochemistry UV-vis 
Cisplatin 6 47 
Carboplatin 6 43 
Gemcitabine 8 25 
Oxoplatin 13 57 
Doxorubicin 17 - 
Pirarubicin 21 45 
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Figure 4. Biosensor response to glucose and amino acids. 
 
To test whether this sensor is responsive to other common metabolites in blood, 
electrochemical studies with several amino acids were performed using SWV. Analyzing Figure 
4, no response was observed for glucose, glycine or tyrosine, while histidine and glutamic acid 
showed a very moderate electrochemical signal change, which is presented by inhibiting the 
anodic peak current in the potential of 0.1 V. This response might be related to the 
electrochemical reaction that occurs between GST and histidine or glutamic acid. We reason that 
the total active metabolite concentration inside a cell is relatively stable, thus creating a stable 
background; the additional anticancer drugs can then still be detected in the presence of these 
background signals. 
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4. CONCLUSION  
In summary, GST is an important detoxification enzyme that plays a critical role in the 
effectiveness of cancer therapy. While most studies focused on its biological roles, in this work, 
we used it as an analytical probe to measure various anticancer drugs. This method is not specific 
to a particle drug but has response to all the tested common anticancer drugs, confirming the 
broad range of substrate for GST. The proposed method showed satisfactory stability and 
detection sensitivity, suggesting that GST immobilized on the electrode surface might be utilized 
for the detection of cisplatin and other anticancer drugs. 
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